Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mayne Cements Place On US Generics Map

Executive Summary

Asset divestments continue in the lead up to Teva's acquisition of Allergan's generics business.

You may also be interested in...

Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.

Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval

Parties have already agreed to sell more than 50 products so far, but are still extending outside date for closing of Teva's acquisition of Allergan's generic business until October.

FTC Review Ongoing As Teva/Allergan Await Final Approval

Analysts had been expecting Teva's acquisition of Allergan's generics business to close at the end of June; Teva insists the acquisition is still going to plan.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts